Straits Times Index
3,384.29 +20.61 (+0.61%) Nikkei
27,509.46 +107.41 (+0.39%) Hang Seng
21,660.47 -297.89 (-1.36%) FTSE 100
7,901.80 +81.64 (+1.04%) BTC-USD
23,393.88 +50.30 (+0.22%) CMC Crypto 200
535.42 -1.43 (-0.27%)
Prothena Corporation plc (PRTA)
After hours:
| Previous close | 55.55 |
| Open | 54.45 |
| Bid | 57.76 x 900 |
| Ask | 60.04 x 1000 |
| Day's range | 54.45 - 58.12 |
| 52-week range | 21.06 - 66.47 |
| Volume | |
| Avg. volume | 568,798 |
| Market cap | 2.981B |
| Beta (5Y monthly) | 0.50 |
| PE ratio (TTM) | 39.29 |
| EPS (TTM) | 1.47 |
| Earnings date | 13 Feb 2023 - 17 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 84.60 |
- Business Wire
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, February 03, 2023--Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Business Wire
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
DUBLIN, January 31, 2023--Prothena announced positive topline Phase 1 SAD study results for PRX005, an investigational tau antibody for the treatment of Alzheimer’s disease.
- Business Wire
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
DUBLIN, December 15, 2022--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering expenses. All of the ordinary shares in the offering were sold by Prothena. In add
